Information Provided By: 
Fly News Breaks for November 19, 2019
RHHBY, NVO, DRNA
Nov 19, 2019 | 08:18 EDT
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna (DRNA) to $30 from $26 and maintained an Outperform rating after the company announced a collaboration with Novo Nordisk (NVO) to develop candidates for liver-related cardiometabolic diseases. In a research note to investors, Foroohar says that while Dicerna's stock has traded up about 30% since the announcement of a partnership with Roche (RHHBY), it remains undervalued.
News For DRNA;NVO;RHHBY From the Last 2 Days
RHHBY
Apr 25, 2024 | 11:44 EDT
NVO
Apr 24, 2024 | 15:59 EDT
Senator Bernie Sanders is set to lead a Senate investigation into the high prices charged by Novo Nordisk for its diabetes and anti-obesity medications Ozempic and Wegovy, The Financial Times' Oliver Barnes reports. Sanders wrote to Novo Nordisk CEO Lars Fruergaard Jorgensen to inform him the U.S. committee that oversees healthcare is probing "the outrageously high prices" the company charges for the drugs, saying that the drugs "will not do any good for the millions of patients who cannot afford them." Reference Link
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
